Cargando…

Nonalcoholic fatty liver disease and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022

BACKGROUND: This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) provides clinicians an overview of nonalcoholic fatty liver disease (NAFLD), potential progression to nonalcoholic steatohepatitis (NASH), and their application to obesity. METHODS: The scientific information for t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karjoo, Sara, Auriemma, Anthony, Fraker, Teresa, Bays, Harold Edward
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661876/ https://www.ncbi.nlm.nih.gov/pubmed/37990727 http://dx.doi.org/10.1016/j.obpill.2022.100027

Ejemplares similares

Cancer and Obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
por: Lazarus, Ethan, et al.
Publicado: (2022)

Thirty Obesity Myths, Misunderstandings, and/or Oversimplifications: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
por: Bays, Harold Edward, et al.
Publicado: (2022)

Stress, psychiatric disease, and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
por: Christensen, Sandra M., et al.
Publicado: (2022)

Concomitant medications, functional foods, and supplements: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
por: Tondt, Justin, et al.
Publicado: (2022)

Bariatric surgery, gastrointestinal hormones, and the microbiome: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
por: Shetye, Bharti, et al.
Publicado: (2022)

Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
por: Bays, Harold E., et al.
Publicado: (2022)

Behavior, motivational interviewing, eating disorders, and obesity management technologies: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
por: Freshwater, Michelle, et al.
Publicado: (2022)

Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023
por: Bays, Harold Edward, et al.
Publicado: (2023)

Nutrition and physical activity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022
por: Alexander, Lydia, et al.
Publicado: (2022)

Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
por: Fitch, Angela K., et al.
Publicado: (2022)

Sleep-disordered breathing, sleep apnea, and other obesity-related sleep disorders: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
por: Pennings, Nicholas, et al.
Publicado: (2022)

Obesity history, physical exam, laboratory, body composition, and energy expenditure: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022
por: Burridge, Karlijn, et al.
Publicado: (2022)

Social consequences and genetics for the child with overweight and obesity: An obesity medicine association (OMA) clinical practice statement 2022
por: Cuda, Suzanne, et al.
Publicado: (2022)

Corrigendum to “Social consequences and genetics for the child with overweight and obesity: An obesity medicine association (OMA) clinical practice statement 2022” [Obes. Pillars 3 (2022) 100032]
por: Cuda, Suzanne, et al.
Publicado: (2022)

Medication-induced weight gain and advanced therapies for the child with overweight and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022
por: Cuda, Suzanne, et al.
Publicado: (2022)

Metabolic, behavioral health, and disordered eating comorbidities associated with obesity in pediatric patients: An Obesity Medical Association (OMA) Clinical Practice Statement 2022
por: Cuda, Suzanne E., et al.
Publicado: (2022)

Assessment, differential diagnosis, and initial clinical evaluation of the pediatric patient with obesity: An Obesity Medical Association (OMA) Clinical Practice Statement 2022
por: Cuda, Suzanne E., et al.
Publicado: (2022)

Nutritional and activity recommendations for the child with normal weight, overweight, and obesity with consideration of food insecurity: An Obesity Medical Association (OMA) Clinical Practice Statement 2022
por: Browne, Nancy T., et al.
Publicado: (2022)

Is There an Association of Vascular Disease and Atherosclerosis in Children and Adolescents With Obesity and Non-alcoholic Fatty Liver Disease?
por: Karjoo, Sara
Publicado: (2018)

Comparison between obese and non-obese nonalcoholic fatty liver disease
por: Chan, Wah-Kheong
Publicado: (2023)

Obesity and nonalcoholic fatty liver disease: current perspectives
por: Sarwar, Raiya, et al.
Publicado: (2018)

Obesity Pillars Roundtable: Obesity and East Asians
por: Bays, Harold Edward, et al.
Publicado: (2022)

Expression of STING in Women with Morbid Obesity and Nonalcoholic Fatty Liver Disease
por: Bertran, Laia, et al.
Publicado: (2023)

The Role of Intestinal Bacteria Overgrowth in Obesity-Related Nonalcoholic Fatty Liver Disease
por: Ferolla, Silvia M., et al.
Publicado: (2014)

Nonalcoholic fatty liver disease in obese and nonobese pediatric patients
por: Kim, Eun Jeong, et al.
Publicado: (2019)

Obesity Pillars Roundtable: Obesity and South Asians
por: Bays, Harold Edward, et al.
Publicado: (2022)

Obesity Pillars Roundtable: Obesity and Diversity
por: Bays, Harold Edward, et al.
Publicado: (2022)

Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals
por: Masuoka, Howard C, et al.
Publicado: (2013)

Surgical treatment of nonalcoholic fatty liver disease in severely obese patients
por: Vander Naalt, Steven J, et al.
Publicado: (2014)

Gut Microbiota and Clinical Disease: Obesity and Nonalcoholic Fatty Liver Disease
por: Park, Ji Sook, et al.
Publicado: (2013)

Obesity, Nonalcoholic Fatty Liver Disease and Adipocytokines Network in Promotion of Cancer
por: Divella, Rosa, et al.
Publicado: (2019)

Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review
por: Hashem, Anas, et al.
Publicado: (2021)

Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease
por: Qadri, Sami, et al.
Publicado: (2021)

Crosstalk between dietary patterns, obesity and nonalcoholic fatty liver disease
por: Ristic-Medic, Danijela, et al.
Publicado: (2022)

Sarcopenic Obesity, the Possible Culprit for Nonalcoholic Fatty Liver Disease or Fibrosis
por: Kang, Seong Hee, et al.
Publicado: (2023)

Endocannabinoid Receptors Gene Expression in Morbidly Obese Women with Nonalcoholic Fatty Liver Disease
por: Auguet, Teresa, et al.
Publicado: (2014)

Comparison of Clinical Characteristics Between Obese and Non-Obese Patients with Nonalcoholic Fatty Liver Disease (NAFLD)
por: Li, Yifang, et al.
Publicado: (2021)

Comparison of cardiometabolic risk factors between obese and non-obese patients with nonalcoholic fatty liver disease
por: Yari, Zahra, et al.
Publicado: (2023)

Obesity pillars roundtable: Obesity and individuals from the Mediterranean region and Middle East
por: Bays, Harold Edward, et al.
Publicado: (2022)

Obesity Pillars roundtable: Excessive weight reduction with highly effective anti-obesity medications (heAOMs)
por: Bays, Harold Edward, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vnb2m6dnqr5mrbtuecr27hg9gc